Ümit Murat ŞAHİNER, Pınar GÜR ÇETİNKAYA

3112

Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder of childhood. Underlying factors thatcontribute to AD are impaired epithelial barrier, alterations in the lipid composition of the skin, immunological imbalance includingincreased Th2/Th1 ratio, proinflammatory cytokines, decreased T regulatory cells, genetic mutations, and epigenetic alterations. Atopicdermatitis is a multifactorial disease with a particularly complicated pathophysiology. Discoveries to date may be considered the tip ofthe iceberg, and the increasing number of studies in this field indicate that there are many points to be elucidated in AD pathophysiology.In this review, we aimed to illustrate the current understanding of the underlying pathogenic mechanisms in AD, to evaluate availabletreatment options with a focus on recently discovered therapeutic agents, and to determine the personal, familial, and economic burdensof the disease, which are frequently neglected issues in AD. Currently available therapies only provide transient solutions and cannotfully cure the disease. However, advances in the understanding of the pathogenic mechanisms of the disease have led to the productionof new treatment options, while ongoing drug trials also have had promising results.
PDF

___

  • 1. Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. Journal of Allergy and Clinical Immunology 1999; 103: 125-138.
  • 2. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide? Journal of Allergy and Clinical Immunology 2008; 121: 947-954.
  • 3. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism 2015; 66: 8-16.
  • 4. Huang E, Ong PY. Severe Atopic Dermatitis in Children. Current Allergy and Asthma Reports 2018; 18: 35-43.
  • 5. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. Journal of Allergy and Clinical Immunology 2003; 112: 252-262.
  • 6. Dharmage S, Lowe A, Matheson M, Burgess J, Allen K et al. Atopic dermatitis and the atopic march revisited. Allergy 2014; 69: 17-27.
  • 7. Bieber T, Novak N. Pathogenesis of atopic dermatitis: new developments. Current Allergy and Asthma Reports 2009; 9: 291- 294.
  • 8. D’Auria E, Banderali G, Barberi S, Gualandri L, Pietra B et al. Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target. Asian Pacific Journal of Allergy and Immunology 2016; 34: 98-108.
  • 9. Mier P. Earliest description of the atopic syndrome? British Journal of Dermatology 1975; 92: 359.
  • 10. Wise F, Sulzberger MB. Year Book of Dermatology and Syphilology. Chicago, IL, USA: Year Book Publishers 1933: 38-39.
  • 11. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy and Clinical Immunology 2009; 124: 1251-1258.
  • 12. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergologia et Immunopathologia 2013; 41: 73-85.
  • 13. Civelek E, Sahiner U, Yüksel H, Boz A, Orhan F et al. Prevalence, burden, and risk factors of atopic eczema in schoolchildren aged 10–11 years: a national multicenter study. Journal of Investigational Allergology and Clinical Immunology 2011; 21: 270-277.
  • 14. DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy & Asthma Proceedings 2012; 33: 227-234.
  • 15. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunology and Allergy Clinics of North America 2010; 30: 269-280.
  • 16. Tada J. Diagnostic standard for atopic dermatitis. Japan Medical Association Journal 2002; 45: 460-465.
  • 17. Hanifin JM. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica 1980; 92: 44-47.
  • 18. De D, Kanwar A, Handa S. Comparative efficacy of Hanifin and Rajka’s criteria and the UK working party’s diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India. Journal of the European Academy of Dermatology and Venereology 2006; 20: 853-859.
  • 19. Williams H, Burney P, Pembroke A, Hay RJ. Validation of the UK diagnostic criteria for atopic dermatitis in a population setting. British Journal of Dermatology 1996; 135: 12-17.
  • 20. Lee SC. Committee of Korean Atopic Dermatitis Association for REACH. Various diagnostic criteria for atopic dermatitis (AD): A proposal of Reliable Estimation of Atopic Dermatitis in Childhood (REACH) criteria, a novel questionnaire‐based diagnostic tool for AD. Journal of Dermatology 2016; 43: 376- 384.
  • 21. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology 2014; 70: 338-351.
  • 22. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR et al. Guidelines of care for atopic dermatitis. Journal of the American Academy of Dermatology 2004; 50: 391-404.
  • 23. Williams H, Jburney P, Hay R, Archer C, Shipley M et al. The UK Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology 1994; 131: 383-396.
  • 24. Strina A, Barreto ML, Cunha S, Maria de Fátima S, Moreira SC et al. Validation of epidemiological tools for eczema diagnosis in Brazilian children: the ISAAC’s and UK Working Party’s criteria. BMC Dermatology 2010; 10: 11-20.
  • 25. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy and Clinical Immunology 2009; 124: 1251-1258.
  • 26. Stalder J, Taieb A, Atherton D, Bieber P, Bonifazi E et al. Severity scoring of atopic dermatitis: the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
  • 27. Oranje AP, Stalder JF, Taïeb A, Tasset C, de Longueville M. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. Pediatric Allergy and Immunology 1997; 8: 28-34.
  • 28. Wolkerstorfer A, De Waard van der Spek F, Glazenburg E, Mulder P, Oranje A. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Dermato-Venereologica 1999; 79: 356-359.
  • 29. Charman C, Venn A, Williams H. Reliability testing of the six area, six sign atopic dermatitis severity score. British Journal of Dermatology 2002; 146: 1057-1060.
  • 30. Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology 2001; 10: 11- 18.
  • 31. Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Current Problems in Dermatology 2011; 41: 149-155.
  • 32. Gelmetti C, Colonna C. The value of SCORAD and beyond: Towards a standardized evaluation of severity? Allergy 2004; 59: 61-65.
  • 33. Krol A, Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatologic Therapy 2006; 19: 73-82.
  • 34. Siegfried E, Hebert A. Diagnosis of atopic dermatitis: mimics, overlaps, and complications. Journal of Clinical Medicine 2015; 4: 884-917.
  • 35. Barrett M, Luu M. Differential diagnosis of atopic dermatitis. Immunology and Allergy Clinics of North America 2017; 37: 11-34.
  • 36. Gaudinski MR, Milner JD. Atopic dermatitis and allergic urticaria: cutaneous manifestations of immunodeficiency. Immunology and Allergy Clinics of North America 2017; 37: 1-10.
  • 37. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunology and Allergy Clinics of North America 2015; 35: 161-183.
  • 38. Saunders SP, Goh CS, Brown SJ, Palmer CN, Porter RM et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. Journal of Allergy and Clinical Immunology 2013; 132: 1121-1129.
  • 39. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nature Genetics 2000; 25: 141-142.
  • 40. Lee H-J, Lee S-H. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy, Asthma & Immunology Research 2014; 6: 276-287.
  • 41. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. Journal of Investigative Dermatology 2005; 124: 198-203.
  • 42. Moniaga CS, Jeong SK, Egawa G, Nakajima S, Hara-Chikuma M et al. Protease activity enhances production of thymic stromal lymphopoietin and basophil accumulation in flaky tail mice. American Journal of Pathology 2013; 182: 841-851.
  • 43. Bager P, Wohlfahrt J, Thyssen JP, Melbye M. Filaggrin genotype and skin diseases independent of atopic dermatitis in childhood. Pediatric Allergy and Immunology 2016; 27: 162-168.
  • 44. Kawasaki H, Nagao K, Kubo A, Hata T, Shimizu A et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. Journal of Allergy and Clinical Immunology 2012; 129: 1538-1546.
  • 45. Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. Journal of Allergy and Clinical Immunology 2014; 134: 792-799.
  • 46. Janssens M, van Smeden J, Gooris GS, Bras W, Portale G et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. Journal of Lipid Research 2012; 53: 2755-2766.
  • 47. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN et al. Tight junction defects in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 2011; 127: 773- 786.
  • 48. Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skinequivalent model treated with interleukin-17. PLoS One 2016; 11: 1-14.
  • 49. Lack G, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. New England Journal of Medicine 2003; 348: 977-985.
  • 50. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101: e8-e.
  • 51. Sybilski AJ, Zalewska M, Furmańczyk K, Lipiec A, KrzychFałta E et al. The prevalence of sensitization to inhalant allergens in children with atopic dermatitis. Allergy & Asthma Proceedings 2015; 36: 81-85.
  • 52. Heilmann C. Adhesion mechanisms of staphylococci. Advances in Experimental Medicine and Biology 2011; 715: 105-123.
  • 53. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. British Journal of Dermatology 1998; 139: 13-16.
  • 54. Kaesler S, Volz T, Skabytska Y, Köberle M, Hein U et al. Tolllike receptor 2 ligands promote chronic atopic dermatitis through IL-4–mediated suppression of IL-10. Journal of Allergy and Clinical Immunology 2014; 134: 92-99.
  • 55. Brauweiler AM, Goleva E, Leung DY. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). Journal of Investigative Dermatology 2014; 134: 2114-2121.
  • 56. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nature Reviews Immunology 2011; 11: 505-518.
  • 57. Brauweiler AM, Bin L, Kim BE, Oyoshi MK, Geha RS et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal α-toxin–induced keratinocyte death. Journal of Allergy and Clinical Immunology 2013; 131: 421- 427.
  • 58. Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. Journal of Allergy and Clinical Immunology 2010; 126: 1184-1190.
  • 59. Raap U, Wichmann K, Bruder M, Ständer S, Wedi B et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. Journal of Allergy and Clinical Immunology 2008; 122: 421- 423.
  • 60. Cho S-H, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW et al. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. Journal of Investigative Dermatology 2001; 116: 658-663.
  • 61. Mempel M, Schmidt T, Weidinger S, Schnopp C, Ring J et al. Role of Staphylococcus aureus surface-associated proteins in the attachment to cultured HaCaT keratinocytes in a new adhesion assay. Journal of Investigative Dermatology 1998; 111: 452-456.
  • 62. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. Journal of Allergy and Clinical Immunology in Practice 2014; 2: 371-379.
  • 63. Bitschar K, Wolz C, Krismer B, Peschel A, Schittek B. Keratinocytes as sensors and central players in the immune defense against Staphylococcus aureus in the skin. Journal of Dermatological Science 2017; 87: 215-220.
  • 64. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the T h1/T h2 paradigm. Allergy 2013; 68: 974-982.
  • 65. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Archives of Dermatology 2012; 148: 890- 897.
  • 66. Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatologic Therapy 2013; 3: 1-15.
  • 67. Aoki W, Ueda M. Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals 2013; 6: 1055-1581.
  • 68. Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. Journal of Allergy and Clinical Immunology 2012; 130: 1344-1354.
  • 69. Henderson J, Northstone K, Lee SP, Liao H, Zhao Y et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. Journal of Allergy and Clinical Immunology 2008; 121: 872-877.
  • 70. Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. Journal of Immunology 2005; 174: 3695-3702.
  • 71. Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. Journal of Allergy and Clinical Immunology 2015; 136: 104-115.
  • 72. Liu Y-J. Thymic stromal lymphopoietin: master switch for allergic inflammation. Journal of Experimental Medicine 2006; 203: 269-273.
  • 73. Omori M, Ziegler S. Induction of IL-4 expression in CD4+ T cells by thymic stromal lymphopoietin. Journal of Immunology 2007; 178: 1396-1404.
  • 74. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. Journal of Clinical and Cellular Immunology 2011; 2: 1-25.
  • 75. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013; 39: 599-610.
  • 76. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. Journal of Investigative Dermatology 2009; 129: 742-751.
  • 77. Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J et al. Periostin in inflammation and allergy. Cellular and Molecular Life Sciences 2017; 74: 4293-4303.
  • 78. Namkung JH, Lee JE, Kim E, Cho HJ, Kim S et al. IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans. Allergy 2007; 62: 934-942.
  • 79. Furue M, Yamamura K, Kido‐Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 2018; 73: 29-36.
  • 80. Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewcz M et al. IL-31 is associated with cutaneous lymphocyte antigenpositive skin homing T cells in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 2006; 117: 418- 425.
  • 81. Kunsleben N, Rüdrich U, Gehring M, Novak N, Kapp A et al. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. Journal of Investigative Dermatology 2015; 135: 1908-1911.
  • 82. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. Journal of Allergy and Clinical Immunology 2015; 135: 324-336.
  • 83. Schittek B. The antimicrobial skin barrier in patients with atopic dermatitis. Current Problems in Dermatology 2011; 41: 54-67.
  • 84. Park H, Li Z, Yang XO, Chang SH, Nurieva R et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology 2005; 6: 1069-1070.
  • 85. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. Journal of Allergy and Clinical Immunology 2003; 111: 875-881.
  • 86. Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. Journal of Allergy and Clinical Immunology 2016; 138: 1639-1651.
  • 87. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nature Reviews Neuroscience 2006; 7: 535-547.
  • 88. Kamo A, Tominaga M, Taneda K, Ogawa H, Takamori K. Neurotropin inhibits the increase in intraepidermal nerve density in the acetone-treated dry-skin mouse model. Clinical and Experimental Dermatology 2013; 38: 665-668.
  • 89. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. Journal of Allergy and Clinical Immunology 2006; 117: 411-417.
  • 90. Wilson SR, Batia LM, Beattie K, Katibah GE, McClain SP et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013; 155: 285-295.
  • 91. Murota H, Katayama I. Evolving understanding on the aetiology of thermally provoked itch. European Journal of Pain 2016; 20: 47-50.
  • 92. Murota H, Izumi M, El-Latif MIA, Nishioka M, Terao M et al. Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. Journal of Allergy and Clinical Immunology 2012; 130: 671-682.
  • 93. Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night’s sleep. International Journal of Molecular Sciences 2016; 17: 425.
  • 94. Williams J, Burr M, Williams H. Factors influencing atopic dermatitis—a questionnaire survey of schoolchildren’s perceptions. British Journal of Dermatology 2004; 150: 1154-1161.
  • 95. Shiohara T, Doi T, Hayakawa J. Defective sweating responses in atopic dermatitis. Current Problems in Dermatology 2011; 41: 68-79.
  • 96. Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind A, Ruschendorf F et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. Nature Genetics 2009; 41: 596-601.
  • 97. Bin L, Leung DY. Genetic and epigenetic studies of atopic dermatitis. Allergy, Asthma & Clinical Immunology 2016; 12: 52.
  • 98. Paternoster L, Standl M, Chen C-M, Ramasamy A, Bønnelykke K et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nature Genetics 2012; 44: 187-192.
  • 99. Wang S, Hon K, Kong A, Tang M, Sy HY et al. Eczema phenotypes are associated with multiple vitamin D pathway genes in Chinese children. Allergy 2014; 69: 118-124.
  • 100. Hussein YM, Shalaby SM, Nassar A, Alzahrani SS, Alharbi AS et al. Association between genes encoding components of the IL-4/IL-4 receptor pathway and dermatitis in children. Gene 2014; 545: 276-281.
  • 101. Amarasekera M, Prescott SL, Palmer DJ. Nutrition in early life, immune-programming and allergies: the role of epigenetics. Asian Pacific Journal of Allergy and Immunology 2013; 31: 175-182.
  • 102. Wang Y, Liang Y, Lu Q. MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clinical Genetics 2008; 74: 307-315.
  • 103. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nature Reviews Genetics 2007; 8: 253-262.
  • 104. Rodríguez E, Baurecht H, Wahn AF, Kretschmer A, Hotze M et al. An integrated epigenetic and transcriptomic analysis reveals distinct tissue-specific patterns of DNA methylation associated with atopic dermatitis. Journal of Investigative Dermatology 2014; 134: 1873-1883.
  • 105. Hinz D, Bauer M, Röder S, Olek S, Huehn J et al. Cord blood T regs with stable FOXP3 expression are influenced by prenatal environment and associated with atopic dermatitis at the age of one year. Allergy 2012; 67: 380-389.
  • 106. Makeyev EV, Maniatis T. Multilevel regulation of gene expression by microRNAs. Science 2008; 319: 1789-1790.
  • 107. Sonkoly E, Janson P, Majuri M-L, Savinko T, Fyhrquist N et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. Journal of Allergy and Clinical Immunology 2010; 126: 581-589.
  • 108. Herberth G, Bauer M, Gasch M, Hinz D, Röder S et al. Maternal and cord blood miR-223 expression associates with prenatal tobacco smoke exposure and low regulatory T-cell numbers. Journal of Allergy and Clinical Immunology 2014; 133: 543-550.
  • 109. Oranje A. Proactive therapy and emollient therapy in atopic dermatitis. Current Treatment Options in Allergy 2014; 1: 365- 373.
  • 110. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology 2014; 71: 116-132.
  • 111. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Pediatric Drugs 2013; 15: 303-310.
  • 112. Draelos ZD. An evaluation of prescription device moisturizers. Journal of Cosmetic Dermatology 2009; 8: 40-43.
  • 113. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J et al. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Annals of Allergy, Asthma & Immunology 2018; 120: 10-22.
  • 114. Dabade TS, Davis DM, Wetter DA, Hand JL, McEvoy MT et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. Journal of the American Academy of Dermatology 2012; 67: 100-106.
  • 115. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009; 123: 808- 814.
  • 116. Sayaseng KY, Vernon P. Pathophysiology and management of mild to moderate pediatric atopic dermatitis. Journal of Pediatric Health Care 2018; 32: 2-12.
  • 117. Barnes TM, Greive KA. Use of bleach baths for the treatment of infected atopic eczema. Australasian Journal of Dermatology 2013; 54: 251-258.
  • 118. Eichenfield L, Totri C. Optimizing outcomes for paediatric atopic dermatitis. British Journal of Dermatology 2014; 170: 31-37.
  • 119. Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta-analysis. Annals of Allergy, Asthma & Immunology 2017; 119: 435-440.
  • 120. Schnopp C, Ring J, Mempel M. The role of antibacterial therapy in atopic eczema. Expert Opinion on Pharmacotherapy 2010; 11: 929-936.
  • 121. Lebon A, Labout JA, Verbrugh HA, Jaddoe VW, Hofman A et al. Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: The Generation R Study. Archives of Pediatrics and Adolescent Medicine 2009; 163: 745-749.
  • 122. Howell MD, Gao P, Kim BE, Lesley LJ, Streib JE et al. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. Journal of Allergy and Clinical Immunology 2011; 128: 1006-1014.
  • 123. Bonamonte D, Belloni Fortina A, Neri L, Patrizi A. Fusidic acid in skin infections and infected atopic eczema. Giornale Italiano di Dermatologia e Venereologia 2014; 149: 453-459.
  • 124. Gelmetti C. Local antibiotics in dermatology. Dermatologic Therapy 2008; 21: 187-195.
  • 125. Travers JB, Kozman A, Yao Y, Ming W, Yao W et al. Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics. Pediatric Dermatology 2012; 29: 289-296.
  • 126. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology 2001; 108: 651-652.
  • 127. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infectious Diseases 2011; 52: 18-55.
  • 128. Aronson PL, Yan AC, Mittal MK, Mohamad Z, Shah SS. Delayed acyclovir and outcomes of children hospitalized with eczema herpeticum. Pediatrics 2011; 128: 1161-1167.
  • 129. Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. International Archives of Allergy and Immunology 2006; 141: 199-212.
  • 130. Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. Alergologia Polska-Polish Journal of Allergology 2017; 4: 158- 168.
  • 131. Thomas K, Williams H, Armstrong S, O’neill C, Avery T et al. Randomized controlled trial of short bursts of a potent topical corticosteroid versus more prolonged use of a mild preparation for children with atopic eczema. British Journal of Dermatology 2002; 146: 541-548.
  • 132. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 2008; 24: 985-994.
  • 133. Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatric Dermatology 2011; 28: 393-396.
  • 134. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic–pituitary–adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105: 794-799.
  • 135. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. Journal of the American Academy of Dermatology 2005; 53: 50-58.
  • 136. Manthripragada AD, Pinheiro SP, MaCurdy TE, Saneinejad S, Worrall CM et al. Off-label topical calcineurin inhibitor use in children. Pediatrics 2013; 132: 1327-1332.
  • 137. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 2005; 6: 65-77.
  • 138. Svensson A, Chambers C, Gånemo A, Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Current Medical Research and Opinion 2011; 27: 1395-1406.
  • 139. El-Batawy MMY, Bosseila MA-W, Mashaly HM, Hafez VSG. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. Journal of Dermatological Science 2009; 54: 76-87.
  • 140. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology 2006; 54: 1-15.
  • 141. Chen S-L, Yan J, Wang F-S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. Journal of Dermatological Treatment 2010; 21: 144-156.
  • 142. Ormerod A. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? British Journal of Dermatology 2005; 153: 701-705.
  • 143. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology 2004; 51: 515-525.
  • 144. Thaci D, Reitamo S, Gonzalez Ensenat M, Moss C, Boccaletti V et al. Proactive disease management with 0· 03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. British Journal of Dermatology 2008; 159: 1348-1356.
  • 145. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006; 61: 969-987.
  • 146. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology 2012; 26: 1045-1060.
  • 147. La Rosa M, Musarra I, Ranno C, Maiello N, Negri L et al. A randomized, double-blind, placebo-controlled, crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis. Current Therapeutic Research 1995; 56: 720- 726.
  • 148. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. American Journal of Medicine 1994; 96: 115-123.
  • 149. Nygaard U, Vestergaard C, Deleuran M. Systemic treatment of severe atopic dermatitis in children and adults. Current Treatment Options in Allergy 2014; 1: 384-396.
  • 150. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. Journal of the American Academy of Dermatology 2003; 49: 1088- 1095.
  • 151. Griffiths C, Katsambas A, Dijkmans B, Finlay A, Ho V et al. Update on the use of ciclosporin in immune-mediated dermatoses. British Journal of Dermatology 2006; 155: 1-16.
  • 152. Madan V, Griffiths CM. Systemic ciclosporin and tacrolimus in dermatology. Dermatologic Therapy 2007; 20: 239-250.
  • 153. Naeyaert J, Lachapelle J, Degreef H, Brassinne Mdl, Heenen M et al. Pharmacology and treatment: cyclosporin in atopic dermatitis. Review of the Literature and Outline of a Belgian Consensus. Dermatology 1999; 198: 45-52
  • 154. Harper J, Ahmed I, Barclay G, Lacour M, Hoeger P et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. British Journal of Dermatology 2000; 142: 52-58.
  • 155. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema–a systematic review and metaanalysis. Journal of the European Academy of Dermatology and Venereology 2007; 21: 606-619.
  • 156. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology 2010; 24: 317-328.
  • 157. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. British Journal of Dermatology 2002; 147: 324-330.
  • 158. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology 2014; 71: 327-349.
  • 159. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. European Journal of Pediatrics 2013; 172: 351-356.
  • 160. Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. International Journal of Dermatology 2014; 53: 1037-1041.
  • 161. Hsu C-J, Wang L-F. Emerging treatment of atopic dermatitis. Clinical Reviews in Allergy & Immunology 2007; 33: 199-203.
  • 162. Grundmann-Kollmann M, Korting H, Behrens S, Leiter U, Krähn G et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. British Journal of Dermatology 1999; 141: 175.
  • 163. Heller M, Shin H, Orlow S, Schaffer J. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. British Journal of Dermatology 2007; 157: 127-132.
  • 164. Downing HJ, Pirmohamed M, Beresford MW, Smyth RL. Paediatric use of mycophenolate mofetil. British Journal of Clinical Pharmacology 2013; 75: 45-59.
  • 165. Ozen A, Baris S, Karakoc EA, Yucelten D, Nadir NB. Experience with intravenous immunoglobulin in severe childhood atopic dermatitis. Allergologia et Immunopathologia 2012; 40: 131-133.
  • 166. Hjuler KP, Vestergaard C, Deleuran M. A retrospective study of six cases of severe recalcitrant atopic dermatitis treated with long-term extracorporeal photopheresis. Acta Dermato-Venereologica 2010; 90: 635-636.
  • 167. Akdis C, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz ME et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Journal of Allergy and Clinical Immunology 2006; 118: 152-169.
  • 168. Schäfer T. The impact of allergy on atopic eczema from data from epidemiological studies. Current Opinion in Allergy and Clinical Immunology 2008; 8: 418-422.
  • 169. Burks AW, Calderon MA, Casale T, Cox L, Demoly P et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. Journal of Allergy and Clinical Immunology 2013; 131: 1288-1296.
  • 170. Martignago I, Incorvaia C, Ridolo E. Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence. Clinical and Molecular Allergy 2017; 15: 13-18.
  • 171. Vidal C, del Río PR, Tabar A, Moreno C. Allergen immunotherapy (AIT) in allergic rhinitis: long-term efficacy and the development of asthma. What do we know? Current Treatment Options in Allergy 2014; 1: 14-26.
  • 172. Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. Journal of Allergy and Clinical Immunology in Practice 2017; 5: 1477-1487.
  • 173. Schneider LC, Baz Z, Zarcone C, Zurakowski D. Long-term therapy with recombinant interferon-gamma (rIFN-γ) for atopic dermatitis. Annals of Allergy, Asthma & Immunology 1998; 80: 263-268.
  • 174. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Archives of Dermatology 1998; 134: 799-804.
  • 175. Presta LG, Lahr S, Shields R, Porter J, Gorman C et al. Humanization of an antibody directed against IgE. Journal of Immunology 1993; 151: 2623-2632.
  • 176. Reddel HK, Bateman ED, Becker A, Boulet L-P, Cruz AA et al. A summary of the new GINA strategy: a roadmap to asthma control. European Research Journal 2015; 46: 622-639.
  • 177. Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. Journal of Allergy and Clinical Immunology 2017; 139: 1431-1444.
  • 178. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. Journal of the American Academy of Dermatology 2006; 54: 68-72.
  • 169. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M et al. Lowdose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. Journal of Allergy and Clinical Immunology 2007; 120: 1223-1225.
  • 180. Amrol D. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. Southern Medical Journal 2010; 103: 554-558.
  • 181. Ghaffari J, Shahmohammadi S, Ashrafi H, Ranjbar AR, Ghaffari N. Omalizumab (Xolair) in children above 12 years with chronic urticaria: a review of literature. Journal of Pediatrics Review 2015; 3: 152-157.
  • 182. Wang H-H, Li Y-C, Huang Y-C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and metaanalysis. Journal of Allergy and Clinical Immunology 2016; 138: 1719-1722.
  • 183. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon H-U. AntiCD20 (rituximab) treatment improves atopic eczema. Journal of Allergy and Clinical Immunology 2008; 121: 122-128.
  • 184. Sediva A, Kayserová J, Vernerová E, Polouckova A, Capkova S et al. Anti-CD20 (rituximab) treatment for atopic eczema. Journal of Allergy and Clinical Immunology 2008; 121: 122- 128.
  • 185. Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology 2014; 134: 1293-1300.
  • 186. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New England Journal of Medicine 2014; 371: 130- 139.
  • 187. Cork M, Thaçi D, DiCioccio T, Davis JD, Zhang Q et al. Pharmacokinetics, safety, and efficacy of dupilumab in a pediatric population with moderate-to-severe atopic dermatitis: results from an open-label phase 2a trial. Presented at: 75th Annual Meeting of the American Academy of Dermatology. Orlando, FL; 2017; 1-15.
  • 188. Cheng JF, Ott NL, Peterson EA, George TJ, Hukee MJ et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. Journal of Allergy and Clinical Immunology 1997; 99: 683-692.
  • 189. Oldhoff J, Darsow U, Werfel T, Katzer K, Wulf A et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693- 696.
  • 190. Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. British Journal of Dermatology 2016; 174: 296-304.
  • 191. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I et al. Anti–interleukin-31 receptor A antibody for atopic dermatitis. New England Journal of Medicine 2017; 376: 826-835.
  • 192. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova J-L et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nature Medicine 2015; 21: 719-729.
  • 193. Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR et al. Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis. Experimental Dermatology 2017; 26: 28-35.
  • 194. Saeki H, Kabashima K, Tokura Y, Murata Y, Shiraishi A et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. British Journal of Dermatology 2017; 177: 419-427.
  • 195. Popovic B, Breed J, Rees D, Gardener M, Vinall L et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol 2017; 429: 208-219.
  • 196. Snast I, Reiter O, Hodak E, Friedland R, Mimouni D et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. American Journal of Clinical Dermatology 2018; 19: 145-165.
  • 197. Patel N, Strowd LC. The future of atopic dermatitis treatment. Advances in Experimental Medicine and Biology 2017; 1027: 185-210.
  • 198. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. Journal of Allergy and Clinical Immunology 2012; 130: 845- 852.
  • 199. Ma P, Bian F, Wang Z, Zheng X, Chotikavanich S et al. Human corneal epithelium-derived thymic stromal lymphopoietin links the innate and adaptive immune responses via TLRs and Th2 cytokines. Investigative Ophthalmology & Visual Science 2009; 50: 2702-2709.
  • 200. Reche PA, Soumelis V, Gorman DM, Clifford T, Liu MR et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. Journal of Immunology 2001; 167: 336-343.
  • 201. Allakhverdi Z, Comeau MR, Jessup HK, Yoon B-RP, Brewer A et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. Journal of Experimental Medicine 2007; 204: 253-258.
  • 202. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nature Immunology 2002; 3: 673-680.
  • 203. Cheng DT, Ma C, Niewoehner J, Dahl M, Tsai A et al. Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma. Journal of Allergy and Clinical Immunology 2013; 132: 455-462.
  • 204. Ahluwalia J, Udkoff J, Waldman A, Borok J, Eichenfield LF. Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook. Drugs 2017; 77: 1389-1397.
  • 205. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson Jr WR et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. Journal of Investigative Dermatology 1996; 107: 51-56.
  • 206. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatology 2014; 150: 593-600.
  • 207. Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. Journal of Investigative Dermatology 2017; 137: 26-30.
  • 208. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ et al. Atopic dermatitis is associated with a decrement in health-related quality of life. International Journal of Dermatology 2002; 41: 151-158.
  • 209. Solomon CR, Gagnon C. Mother and child characteristics and involvement in dyads in which very young children have eczema. Journal of Developmental and Behavioral Pediatrics 1987; 8: 213-220.
  • 210. Chamlin SL, Frieden IJ, Williams ML, Chren M-M. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004; 114: 607-611.
  • 211. Ballardini N, Östblom E, Wahlgren C-F, Kull I. Mild eczema affects self-perceived health among pre-adolescent girls. Acta Dermato-Venereologica 2014; 94: 312-316.
  • 212. Ho RC, Giam Y, Ng T, Mak A, Goh D et al. The influence of childhood atopic dermatitis on health of mothers, and its impact on Asian families. Pediatric Allergy and Immunology 2010; 21: 501-507.
  • 213. Sánchez-Pérez J, Daudén-Tello E, Mora A, Surinyac NL. Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. ACTAS Dermo-Sifiliográficas (English Edition). 2013; 104: 44-52.
  • 214. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Archives of Disease in Childhood 1997; 76: 159-162.
  • 215. Ring J, Palos E. Psychosomatic aspects of parent–child relations in atopic eczema in childhood. II. Child-rearing style, the family situation in a drawing test and structured interview. Hautarzt 1986; 37: 609-617.
  • 216. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Medicine and Health/Rhode Island 2001; 84: 294-295.
  • 217. Carroll CL, Balkrishnan R, Feldman SR, Fleischer Jr AB, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatric Dermatology 2005; 22: 192-199.
  • 218. Lee BW, Detzel PR. Treatment of childhood atopic dermatitis and economic burden of illness in Asia Pacific countries. Annals of Nutrition and Metabolism 2015; 66: 18-24.
  • 219. Storan ER, McEvoy MT, Wetter DA, el-Azhary RA, Hand JL et al. Pediatric hospital dermatology: experience with inpatient and consult services at the Mayo Clinic. Pediatric Dermatology 2013; 30: 433-437.
  • 220. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C et al. The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology 2006; 55: 490-500.
  • 221. Patel NU, D’Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. American Journal of Clinical Dermatology 2017; 18: 323-332.
  • 222. Margolis DJ, Gupta J, Apter AJ, Ganguly T, Hoffstad O et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African-American subjects. Journal of Allergy and Clinical Immunology 2014; 133: 784-789.
  • 223. Lan CCE, Tu HP, Wu CS, Ko YC, Yu HS et al. Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population. Experimental Dermatology 2011; 20: 975-979.
  • 224. Fortugno P, Furio L, Teson M, Berretti M, El Hachem M et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Human Molecular Genetics 2012; 21: 4187-4200.
  • 225. Yu H-S, Kang M-J, Kwon J-W, Lee S-Y, Lee E et al. Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE. Journal of Allergy and Clinical Immunology 2015; 135: 827-830.
  • 226. Ismaïl A, Bousaffara R, Kaziza J, Zili J, El Kamel A, Sfar MT et al. Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians. Journal of Allergy and Clinical Immunology 1997; 99: 216-223.
  • 227. Braff MH, Di Nardo A, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. Journal of Investigative Dermatology 2005; 124: 394-400.
  • 228. Levchenko L, Izmaĭlova O, Shlykova O, Kaĭdashev I. Polymorphism 896A/G of TLR4 gene rather than 1196C/T and 2258G/A of TLR2 gene determines severe and complicated course of atopic dermatitis in children. Tsitologiia i genetika 2013; 47: 46-53.
  • 229. Potaczek DP, Nastalek M, Okumura K, Wojas-Pelc A, Undas A et al. An association of TLR2–16934A> T polymorphism and severity/phenotype of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology 2011; 25: 715-721.
  • 230. Oh DY, Schumann R, Hamann L, Neumann K, Worm M et al. Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis. Allergy 2009; 64: 1608-1615.
  • 231. Salpietro C, Rigoli L, Del Giudice MM, Cuppari C, Di Bella C et al. TLR2 and TLR4 gene polymorphisms and atopic dermatitis in Italian children: a multicenter study. International Journal of Immunopathology and Pharmacology 2011; 24: 33-40.
  • 232. Weidinger S, Rümmler L, Klopp N, Wagenpfeil S, Baurecht H et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 2005; 60: 1256-1261.
  • 233. Margolis DJ, Kim B, Apter AJ, Gupta J, Hoffstad O et al. Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis. JAMA Dermatology 2014; 150: 254-259.
  • 234. Ma CA, Stinson JR, Zhang Y, Abbott JK, Weinreich MA et al. Germline hypomorphic CARD11 mutations in severe atopic disease. Nature Genetics 2017; 49: 1192-2101.
  • 235. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics 2012; 44: 1341-1348.
  • 236. Kabesch M, Peters W, Carr D, Leupold W, Weiland SK et al. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. Journal of Allergy and Clinical Immunology 2003; 111: 813-817.
  • 237. Gao P-S, Rafaels NM, Mu D, Hand T, Murray T et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. Journal of Allergy and Clinical Immunology 2010; 12: 1403-1407.
  • 238. Kim E, Lee JE, Namkung JH, Kim PS, Kim S et al. Single nucleotide polymorphisms and the haplotype in the DEFB1 gene are associated with atopic dermatitis in a Korean population. Journal of Dermatological Science 2009; 54: 25-30.
  • 239. Kayserova J, Sismova K, Zentsova-Jaresova I, Katina S, Vernerova E et al. A prospective study in children with a severe form of atopic dermatitis: clinical outcome in relation to cytokine gene polymorphisms. Journal of Investigational Allergology and Clinical Immunology 2012; 22: 92-101.
  • 240. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B et al. Gene polymorphism in Netherton and common atopic disease. Nature Genetics 2001; 29: 175-178.
  • 241. Chang Y, Lee W, Yu C, Liu H, Lin M et al. No association of cytokine gene polymorphisms in Chinese patients with atopic dermatitis. Clinical and Experimental Dermatology 2006; 31: 419-423.
  • 242. Sokołowska-Wojdyło M, Gleń J, Zabłotna M, Rębała K, Trzeciak M et al. The frequencies of haplotypes defined by three polymorphisms of the IL‐31 gene:− 1066,− 2057, and IVS 2+ 12 in Polish patients with atopic dermatitis. International Journal of Dermatology 2015; 54: 62-67.
  • 243. Narbutt J, Wojtczak M, Zalińska A, Salinski A, PrzybylowskaSygut K et al. The A/A genotype of an interleukin‐17A polymorphism predisposes to increased severity of atopic dermatitis and coexistence with asthma. Clinical and Experimental Dermatology 2015; 40: 11-16.
  • 244. Namkung J-H, Lee J-E, Kim E, Park GT, Yang HS et al. An association between IL-9 and IL-9 receptor gene polymorphisms and atopic dermatitis in a Korean population. Journal of Dermatological Science 2011; 62: 16-21.
  • 245. Novak N, Kruse S, Potreck J, Maintz L, Jenneck C et al. Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. Journal of Allergy and Clinical Immunology 2005; 115: 828-833.
  • 246. Rafatpanah H, Bennett E, Pravica V, McCoy MJ, David TJ et al. Association between novel GM-CSF gene polymorphisms and the frequency and severity of atopic dermatitis. Journal of Allergy and Clinical Immunology 2003; 112: 593-598.
  • 247. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC et al. Atopic dermatitis is associated with a functional mutation in the promoter of the CC chemokine RANTES. Journal of Immunology 2000; 164: 1612-1616.
  • 248. Tanaka K, Roberts M, Yamamoto N, Sugiura H, Uehara M et al. Upregulating promoter polymorphisms of RANTES relate to atopic dermatitis. International Journal of Immunogenetics 2006; 33: 423-428.
  • 249. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K et al. Eotaxin gene single nucleotide polymorphisms in the promoter and exon regions are not associated with susceptibility to atopic dermatitis, but two of them in the promoter region are associated with serum IgE levels in patients with atopic dermatitis. Journal of Dermatological Science 2002; 29: 222-228.
  • 250. Gangur V, Oppenheim JJ. Are chemokines essential or secondary participants in allergic responses? Annals of Allergy, Asthma & Immunology 2000; 84: 569-581.
  • 251. Hallau J, Hamann L, Schumann RR, Worm M, Heine G. A promoter polymorphism of the vitamin D metabolism gene Cyp24a1 is associated with severe atopic dermatitis in adults. Acta Dermato-Venereologica 2016; 96: 169-172.
  • 252. Yang K, Liu CA, Chang JC, Chuang H, Ou CY et al. Polymorphism of the immune-braking gene CTLA-4 (+ 49) involved in gender discrepancy of serum total IgE levels and allergic diseases. Clinical & Experimental Allergy 2004; 34: 32-37.
  • 253. Nishio Y, Noguchi E, Ito S, Ichikawa E, Umebayashi Y et al. Mutation and association analysis of the interferon regulatory factor 2 gene (IRF2) with atopic dermatitis. Journal of Human Genetics 2001; 46: 664-667.
  • 254. Howell M, Parker M, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy 2015; 70: 887-896.
  • 255. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T et al. Difficult to control atopic dermatitis. World Allergy Organization Journal 2013; 6: 1-6.
  • 256. Bell DC, Brown SJ. Atopic eczema treatment now and in the future: Targeting the skin barrier and key immune mechanisms in human skin. World Journal of Dermatology 2017; 6: 42-51.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

The association between levels of inflammatory markers in autistic children compared to their unaffected siblings and unrelated healthy controls

Yasmeen Z. QWAIDER, Sultan S. ABDELHAMID, Loai ALZGHOUL, Mohammad ALDAHABI, Ahmad H. YANIS, Suzan A. ALBDOUR

Yaşar TÜRK, Artür SALMASLIOĞLU, Hadi SASANİ

Mohammed ELSHIEKH, Mehri KADKHODAEE, Behjat SEIFI, Mina RANJBARAN

Okan KIZILYEL, Necmettin AKDENİZ, Mahmut Sami METİN, Ömer Faruk ELMAS

Ovarian stimulation modalities in poor responders

Zehra Sema ÖZKAN

Nurten Gizem TORE, Mesken GÜMÜŞSOY, Deran OSKAY

Tuğba ATAN, Özden Özyemişci TAŞKIRAN, Ayşe Bora TOKÇAER, Gülçin Kaymak KARATAŞ, Asli Karakuş ÇALIŞKAN, Belgin KARAOĞLAN

Zeliha Güzelöz ÇAPAR, Lütfiye Zümre Arican ALICIKUŞ, Nesrin AKTÜRK, Merih Güray DURAK, Ali İbrahim SEVİNÇ, Pinar BALCI, İlknur GÖRKEN

Berker DUMAN, Zeynep KOTAN, Vahap Ozan KOTAN, Nevzat Mehmet MUTLU, Beyza Doğanay ERDOĞAN, Damla Sayar AKASLAN, Safiye Zeynep TATLI, Hakan KUMBASAR

Ferhan KERGET, Zülal ÖZKURT, Nurinnisa ÖZTÜRK, Sinan YILMAZ